Tubulozole-induced G2/M cell cycle arrest in human colon cancer cells through formation of microtubule polymerization mediated by ERK1/2 and Chk1 kinase activation

Food and Chemical Toxicology

Volumn 45, Issue 8, 2007, Pages 1356-1367

  Chou, Yean Hwei ^a   Ho, Yuan Soon ^b   Wu, Chi Chen ^c   Chai, Chiah Yang ^a   Chen, Soul Chin ^a   Lee, Chia Hwa ^b   Tsai, Pei Shan ^b   Wu, Chih Hsiung ^a  

^a Georgetown Univ School of Medicine   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chk1; Colon cancer; ERK1 2; G2 M arrest; Tubulozole

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CHECKPOINT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOCODAZOLE; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN TYROSINE PHOSPHATASE; SMALL INTERFERING RNA; TUBULOZOLE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; COLONIC NEOPLASMS; DIOXOLANES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; G2 PHASE; HL-60 CELLS; HT29 CELLS; HUMANS; MICROTUBULES; PHOSPHORYLATION; PROTEIN KINASES; RNA, SMALL INTERFERING;

CITRUS MACROPHYLLA;

EID: 34447094915     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2007.01.012     Document Type: Article

References (82)

1. Advani S.J., Brandimarti R., Weichselbaum R.R., and Roizman B. The disappearance of cyclins A and B and the increase in activity of the G(2)/M-phase cellular kinase cdc2 in herpes simplex virus 1-infected cells require expression of the alpha22/U(S)1.5 and U(L)13 viral genes. J. Virol. 74 1 (2000) 8-15
2. Ahamed S., Foster J.S., Bukovsky A., and Wimalasena J. Signal transduction through the Ras/Erk pathway is essential for the mycoestrogen zearalenone-induced cell-cycle progression in MCF-7 cells. Mol. Carcinog. 30 2 (2001) 88-98
3. Bacus S.S., Gudkov A.V., Lowe M., Lyass L., Yung Y., Komarov A.P., Keyomarsi K., Yarden Y., and Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20 2 (2001) 147-155
4. Bhonde M.R., Hanski M.L., Magrini R., Moorthy D., Muller A., Sausville E.A., Kohno K., Wiegand P., Daniel P.T., Zeitz M., and Hanski C. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene 24 1 (2005) 148-156
5. Bressac B., Galvin K.M., Liang T.J., Isselbacher K.J., Wands J.R., and Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 87 5 (1990) 1973-1977
6. 2+]i modifications and cytoskeletal disorganization in glial (GL15) and neuronal-like (PC12) cell lines. Arch. Pharm. (Weinheim) 333 11 (2000) 373-380
7. Chen R.J., Lee W.S., Liang Y.C., Lin J.K., Wang Y.J., Lin C.H., Hsieh J.Y., Chaing C.C., and Ho Y.S. Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. Toxicol. Appl. Pharmacol. 169 2 (2000) 132-141
8. Cho S.H., Toouli C.D., Fujii G.H., Crain C., and Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 4 1 (2005) 131-139
9. Cunningham D., and Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer. A 29 15 (1993) 2077-2079
10. Dai Y., Rahmani M., Pei X.Y., Khanna P., Han S.I., Mitchell C., Dent P., and Grant S. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105 4 (2005) 1706-1716
11. de Vos tot Nederveen Cappel W.H., Meulenbeld H.J., Kleibeuker J.H., Nagengast F.M., Menko F.H., Griffioen G., Cats A., Morreau H., Gelderblom H., and Vasen H.F. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int. J. Cancer 109 3 (2004) 468-471
12. Distelmans W., Van Ginckel R., Vanherck W., Willebrords R., Wouters L., De Brabander M., and Mesens J. Erbulozole (P.I.N.N.) (R 55 104) encapsulated into cyclodextrins: has it a combined antitumoral and radioprotective potential?. Anticancer Res. 11 1 (1991) 253-256
13. Dunphy W.G. The decision to enter mitosis. Trends Cell. Biol. 4 6 (1994) 202-207
14. Einzig A.I., Neuberg D., Wiernik P.H., Grochow L.B., Ramirez G., O'Dwyer P.J., and Petrelli N.J. Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: an eastern cooperative oncology group trial (PA286). Am. J. Ther. 3 11 (1996) 750-754
15. Facchinetti M.M., De Siervi A., Toskos D., and Senderowicz A.M. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res. 64 10 (2004) 3629-3637
16. Fong D. Effect of the anti-microtubule compound tubulozole on Leishmania protozoan parasites in vitro. FEMS Microbiol. Lett. 107 1 (1993) 95-99
17. Fujii T., Tachibana M., Dhar D.K., Ueda S., Kinugasa S., Yoshimura H., Kohno H., and Nagasue N. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res. 23 3B (2003) 2405-2411
18. Furnari B., Rhind N., and Russell P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277 5331 (1997) 1495-1497
19. Geuens G.M., Nuydens R.M., Willebrords R.E., Van de Veire R.M., Goossens F., Dragonetti C.H., Mareel M.M., and De Brabander M.J. Effects of tubulozole on the microtubule system of cells in culture and in vivo. Cancer Res. 45 2 (1985) 733-742
20. Han E.K., Butler C., Zhang H., Rosenberg S., Giranda V.L., Ng S.C., Luo Y., Severin J.M., Qin W., Holzman T.F., Gubbins E.J., and Simmer R.L. Chkl binds and phosphorylates BAD protein. Anticancer Res. 24 6 (2004) 3907-3910
21. Ho Y.S., Wang Y.J., and Lin J.K. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol. Carcinog. 16 1 (1996) 20-31
22. Ho Y.S., Tsai P.W., Yu C.F., Liu H.L., Chen R.J., and Lin J.K. Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. Toxicol. Appl. Pharmacol. 153 1 (1998) 39-47
23. Ho Y.S., Duh J.S., Jeng J.H., Wang Y.J., Liang Y.C., Lin C.H., Tseng C.J., Yu C.F., Chen R.J., and Lin J.K. Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells. Int. J. Cancer 91 3 (2001) 393-401
24. Ho C.C., Siu W.Y., Chow J.P., Lau A., Arooz T., Tong H.Y., Ng I.O., and Poon R.Y. The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint. Exp. Cell. Res. 304 1 (2005) 1-15
25. Huang T.S., Shu C.H., Chao Y., Chen S.N., and Chen L.L. Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 5 3 (2000) 235-241
26. Huang X., Tran T., Zhang L., Hatcher R., and Zhang P. DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc. Natl. Acad. Sci. USA 102 4 (2005) 1065-1070
27. Jalal Hosseinimehr S., Inanami O., Hamasu T., Takahashi M., Kashiwakura I., Asanuma T., and Kuwabara M. Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in HL60 cells. J. Radiat. Res. (Tokyo) 45 4 (2004) 557-561
28. Jiang K., Pereira E., Maxfield M., Russell B., Goudelock D.M., and Sanchez Y. Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345. J. Biol. Chem. 278 27 (2003) 25207-25217
29. Jordan M.A., and Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell. Biol. 10 1 (1998) 123-130
30. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 3 4 (2004) 513-519
31. Knowles B.B., Howe C.C., and Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209 4455 (1980) 497-499
32. Lee J., Kumagai A., and Dunphy W.G. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol. Biol. Cell. 12 3 (2001) 551-563
33. Lee W.S., Chen R.J., Wang Y.J., Tseng H., Jeng J.H., Lin S.Y., Liang Y.C., Chen C.H., Lin C.H., Lin J.K., Ho P.Y., Chu J.S., Ho W.L., Chen L.C., and Ho Y.S. In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest. Int. J. Cancer 106 1 (2003) 125-137
34. Levesque A.A., Kohn E.A., Bresnick E., and Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 24 23 (2005) 3786-3796
35. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., and Elledge S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14 12 (2000) 1448-1459
36. MacCormick M., Moderscheim T., van der Salm L.W., Moore A., Pryor S.C., McCaffrey G., and Grimes M.L. Distinct signaling particles containing ERK/MEK and B-Raf in PC12 cells. Biochem J. 387 Pt 1 (2005) 155-164
37. MacKeigan J.P., Collins T.S., and Ting J.P. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem. 275 50 (2000) 38953-38956
38. Mandic A., Viktorsson K., Heiden T., Hansson J., and Shoshan M.C. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 11 1 (2001) 11-19
39. Margolis S.S., Walsh S., Weiser D.C., Yoshida M., Shenolikar S., and Kornbluth S. PP1 control of M phase entry exerted through 14-3-3-regulated Cdc25 dephosphorylation. Embo J. 22 21 (2003) 5734-5745
40. Masters S.C., Yang H., Datta S.R., Greenberg M.E., and Fu H. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol. Pharmacol. 60 6 (2001) 1325-1331
41. Matsuoka S., Huang M., and Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 5395 (1998) 1893-1897
42. McGowan C.H., and Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. Embo J. 12 1 (1993) 75-85
43. McGowan C.H., and Russell P. Cell cycle regulation of human WEE1. Embo J. 14 10 (1995) 2166-2175
44. Niewolik D., Vojtesek B., and Kovarik J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10 5 (1995) 881-890
45. Nyberg K.A., Michelson R.J., Putnam C.W., and Weinert T.A. Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet. 36 (2002) 617-656
46. Oliver R.H., Khan S.M., Leung B.S., and Yeh J. Induction of apoptosis in luteinized granulosa cells by the MAP kinase kinase (MEK) inhibitor PD98059. Biochem. Biophys. Res. Commun. 263 1 (1999) 143-148
47. Palermo C., and Walworth N.C. Assaying cell cycle checkpoints: activity of the protein kinase Chk1. Methods Mol. Biol. 296 (2005) 345-354
48. Ren Q., Liu R., Dicker A., and Wang Y. CHK1 affects cell sensitivity to microtubule-targeted drugs. J. Cell. Physiol. 203 1 (2005) 273-276
49. Rouzier, R., Rajan, R., Wagner, P., Hess, K.R., Gold, D.L., Stec, J., Ayers, M., Ross, J.S., Zhang, P., Buchholz, T.A., Kuerer, H., Green, M., Arun, B., Hortobagyi, G.N., Symmans, W.F., Pusztai, L., 2005. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc. Natl. Acad. Sci. USA.
50. Samarakoon R., and Higgins P.J. MEK/ERK pathway mediates cell-shape-dependent plasminogen activator inhibitor type 1 gene expression upon drug-induced disruption of the microfilament and microtubule networks. J. Cell. Sci. 115 Pt 15 (2002) 3093-3103
51. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., and Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73 (2004) 39-85
52. Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H., and Elledge S.J. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277 5331 (1997) 1497-1501
53. Schippinger W., Jagoditsch M., Sorre C., Gnant M., Steger G., Hausmaninger H., Mlineritsch B., Schaberl-Moser R., Mischinger H.J., Hofbauer F., Holzberger P., Mittlbock M., and Jakesz R. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br. J. Cancer 92 9 (2005) 1655-1662
54. Scholey J.M., Brust-Mascher I., and Mogilner A. Cell division. Nature 422 6933 (2003) 746-752
55. Seidman R., Gitelman I., Sagi O., Horwitz S.B., and Wolfson M. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp. Cell. Res. 268 1 (2001) 84-92
56. Seiler N., Schneider Y., Gosse F., Schleiffer R., and Raul F. Polyploidisation of metastatic colon carcinoma cells by microtubule and tubulin interacting drugs: effect on proteolytic activity and invasiveness. Int. J. Oncol. 25 4 (2004) 1039-1048
57. Shao R.G., Cao C.X., and Pommier Y. Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells. Acta. Pharmacol. Sin. 25 6 (2004) 756-762
58. Siddiqui K.M., and Chopra D.P. Primary and long term epithelial cell cultures from human fetal normal colonic mucosa. In Vitro 20 11 (1984) 859-868
59. Singh S.V., Herman-Antosiewicz A., Singh A.V., Lew K.L., Srivastava S.K., Kamath R., Brown K.D., Zhang L., and Baskaran R. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J. Biol. Chem. 279 24 (2004) 25813-25822
60. Sorensen C.S., Hansen L.T., Dziegielewski J., Syljuasen R.G., Lundin C., Bartek J., and Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell. Biol. 7 2 (2005) 195-201
61. Stadheim T.A., Xiao H., and Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res. 61 4 (2001) 1533-1540
62. Stitt A.W., and Fairweather I. Fasciola hepatica: the effect of the microtubule inhibitors colchicine and tubulozole-C on the ultrastructure of the adult fluke. Parasitology 107 Pt 3 (1993) 297-309
63. Stracke M.L., Soroush M., Liotta L.A., and Schiffmann E. Cytoskeletal agents inhibit motility and adherence of human tumor cells. Kidney Int. 43 1 (1993) 151-157
64. Takagaki K., Katsuma S., Kaminishi Y., Horio T., Tanaka T., Ohgi T., and Yano J. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells. Genes Cells 10 2 (2005) 97-106
65. Tenzer A., and Pruschy M. Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Curr. Med. Chem. Anti-Canc Agents 3 1 (2003) 35-46
66. Tse A.N., and Schwartz G.K. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 64 18 (2004) 6635-6644
67. Van Belle S.J., Distelmans W., Vandebroek J., Bruynseels J., Van Ginckel R., and Storme G.A. Phase I trial of erbulozole (R55104). Anticancer Res. 13 6B (1993) 2389-2391
68. Vasquez R.J., Howell B., Yvon A.M., Wadsworth P., and Cassimeris L. Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. Mol. Biol. Cell. 8 6 (1997) 973-985
69. Wang Y.J., Jeng J.H., Chen R.J., Tseng H., Chen L.C., Liang Y.C., Lin C.H., Chen C.H., Chu J.S., Ho W.L., and Ho Y.S. Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice. Mol. Carcinog. 34 4 (2002) 199-210
70. Wang Y.J., Yu C.F., Chen L.C., Chen C.H., Lin J.K., Liang Y.C., Lin C.H., Lin S.Y., Chen C.F., and Ho Y.S. Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. J. Cell. Biochem. 87 2 (2002) 147-159
71. Wang Y., Decker S.J., and Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol. Ther. 3 3 (2004) 305-313
72. Welsh G.I., Hall D.A., Warnes A., Strange P.G., and Proud C.G. Activation of microtubule-associated protein kinase (Erk) and p70 S6 kinase by D2 dopamine receptors. J. Neurochem. 70 5 (1998) 2139-2146
73. Wilker, E.W., Grant, R.A., Artim, S.C., Yaffe, M.B., 2005. A structural basis for 14-3-3 sigma functional specificity. J. Biol. Chem.
74. Wu C.H., Jeng J.H., Wang Y.J., Tseng C.J., Liang Y.C., Chen C.H., Lee H.M., Lin J.K., Lin C.H., Lin S.Y., Li C.P., and Ho Y.S. Antitumor effects of miconazole on human colon carcinoma xenografts in nude mice through induction of apoptosis and G0/G1 cell cycle arrest. Toxicol. Appl. Pharmacol. 180 1 (2002) 22-35
75. Xiao, Z., Xue, J., Semizarov, D., Sowin, T.J., Rosenberg, S.H., Zhang, H., 2005a. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int. J. Cancer.
76. Xiao Z., Xue J., Semizarov D., Sowin T.J., Rosenberg S.H., and Zhang H. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int. J. Cancer 115 4 (2005) 528-538
77. Xiao Z., Xue J., Sowin T.J., Rosenberg S.H., and Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24 8 (2005) 1403-1411
78. Yan Y., and Mumby M.C. Distinct roles for PP1 and PP2A in phosphorylation of the retinoblastoma protein. PP2a regulates the activities of G(1) cyclin-dependent kinases. J. Biol. Chem. 274 45 (1999) 31917-31924
79. Yu C., Dai Y., Dent P., and Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. Cancer Biol. Ther. 1 6 (2002) 674-682
80. Yu Q., La Rose J., Zhang H., Takemura H., Kohn K.W., and Pommier Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 62 20 (2002) 5743-5748
81. Zelivianski S., Spellman M., Kellerman M., Kakitelashvilli V., Zhou X.W., Lugo E., Lee M.S., Taylor R., Davis T.L., Hauke R., and Lin M.F. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int. J. Cancer 107 3 (2003) 478-485
82. Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T., Johanson K.O., Green S.M., Concha N.O., and Zhou B.B. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 277 48 (2002) 46609-46615